Talphera Inc (FRA:R5XA)
€ 0.657 -0.013 (-1.94%) Market Cap: 11.40 Mil Enterprise Value: 1.64 Mil PE Ratio: 0 PB Ratio: 1.25 GF Score: 34/100

Q3 2019 AcelRx Pharmaceuticals Inc Earnings Call Transcript

Nov 06, 2019 / 10:00PM GMT
Release Date Price: €35.83 (-1.21%)
Operator

Good day, and welcome to the AcelRxâ third quarter 2019 conference call. This call is being webcast live on the Events page of the Investors section of AcelRx' website at acelrx.com. This call is the property of AcelRx and any recording, reproduction or transmission of this call without the expressed written consent of AcelRx is strictly prohibited. As a reminder, today's call is being recorded. You may listen to a webcast replay of this call by going to the Investors section of AcelRx' website.

I would now like to turn the call over to Raffi Asadorian, AcelRx' Chief Financial Officer. Please go ahead, sir.

Raffi Mark Asadorian
AcelRx Pharmaceuticals, Inc. - CFO

Thank you for joining us this afternoon. Earlier today, we reported our third quarter 2019 financial results and provided an update on our commercial launch of DSUVIA in a press release. This press release and the slide presentation accompanying this call are available in the Investors section of our website.

With me today are Vince Angotti, our Chief Executive Officer; and Dr. Pam

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot